ARCHIVES

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

FDA: Silicone Breast Implants Safe, But Not “Lifetime Device”

June 24, 2011

FDA Subcommittee Leaning Toward Mouse-Dog Drug Testing New Preclinical Toxicity-Protocol

July 20, 1979

Center For Health Policy And Outcomes Established At Memorial Sloan Kettering. ONS Marks 35th Year.

July 9, 2010

AACR President: Cancer Program ‘Threatened,’ Calls For Strategic Plan, More Extramural Input

December 6, 1991

Sustained-Release Leuprolide Under Study In Phase III Trial.

June 30, 2000

FDA Allows Firms To Distribute Reprints On Unapproved Uses of Products

January 16, 2009